Previous close | 2.2500 |
Open | 2.5000 |
Bid | 2.1000 |
Ask | 3.9000 |
Strike | 30.00 |
Expiry date | 2024-11-15 |
Day's range | 2.5000 - 2.5000 |
Contract range | N/A |
Volume | |
Open interest | 4 |
On June 7, 2024, Diane Young, Senior Vice President and Chief Medical Officer of Celldex Therapeutics Inc (NASDAQ:CLDX), sold 45,000 shares of the company.
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage b
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data further support barzolvolimab clinical benefit to patients with CSU - HAMPTON, N.J., June 02, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in c